Literature DB >> 23671484

The diagnosis and treatment of generalized anxiety disorder.

Borwin Bandelow1, Reinhard Boerner J, Siegfried Kasper, Michael Linden, Hans-Ulrich Wittchen, Hans-Jürgen Möller.   

Abstract

BACKGROUND: Generalized anxiety disorder (GAD) is a common and serious disease with a lifetime prevalence of 4.3% to 5.9%. It is underdiagnosed in primary care.
METHODS: Recommendations on the treatment of GAD are given on the basis of all available findings from pertinent randomized trials, retrieved by a selective search of the literature.
RESULTS: Among psychotherapeutic techniques, various kinds of cognitive behavioral therapy (CBT) have been found useful in controlled trials. The drugs of first choice include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephine reuptake inhibitors (SNRIs), and the calcium-channel modulator pregabalin. Tricyclic antidepressants are also effective but have more adverse effects than SSRIs. Although benzodiazepines are effective anxiolytic agents for short-term use, they should not be given over the long term because of the danger of addiction. Buspirone, an azapirone, was found to be effective in a small number of trials, but the findings across trials are inconsistent. The response rate of GAD to CBT in published studies lies between 47% and 75%, while its response rate to drug treatment lies between 44% and 81%.
CONCLUSION: The treatment of GAD with CBT and drugs is evidence-based and has a good chance of improving the manifestations of the disorder.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23671484      PMCID: PMC3651952          DOI: 10.3238/arztebl.2013.0300

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  116 in total

1.  Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment.

Authors:  Karl Rickels; Thomas M Shiovitz; Tanya S Ramey; Jerry J Weaver; Lloyd E Knapp; Jeffrey J Miceli
Journal:  Int Clin Psychopharmacol       Date:  2012-05       Impact factor: 1.659

2.  A controlled trial of treatments for generalized anxiety.

Authors:  W R Lindsay; C V Gamsu; E McLaughlin; E M Hood; C A Espie
Journal:  Br J Clin Psychol       Date:  1987-02

3.  Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder.

Authors:  T D Borkovec; E Costello
Journal:  J Consult Clin Psychol       Date:  1993-08

4.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

5.  Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: evaluation in a controlled clinical trial.

Authors:  R Ladouceur; M J Dugas; M H Freeston; E Léger; F Gagnon; N Thibodeau
Journal:  J Consult Clin Psychol       Date:  2000-12

6.  Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.

Authors:  Martin A Katzman; Olga Brawman-Mintzer; Efren B Reyes; Bengt Olausson; Sherry Liu; Hans Eriksson
Journal:  Int Clin Psychopharmacol       Date:  2011-01       Impact factor: 1.659

7.  Pregabalin in generalized anxiety disorder: a placebo-controlled trial.

Authors:  Atul C Pande; Jerri G Crockatt; Douglas E Feltner; Carol A Janney; Ward T Smith; Richard Weisler; Peter D Londborg; Robert J Bielski; Dan L Zimbroff; Jonathan R T Davidson; Maria Liu-Dumaw
Journal:  Am J Psychiatry       Date:  2003-03       Impact factor: 18.112

8.  Internet treatment for generalized anxiety disorder: a randomized controlled trial comparing clinician vs. technician assistance.

Authors:  Emma Robinson; Nickolai Titov; Gavin Andrews; Karen McIntyre; Genevieve Schwencke; Karen Solley
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

9.  Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder.

Authors:  R Enkelmann
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

10.  A family study of generalized anxiety disorder.

Authors:  R Noyes; C Clarkson; R R Crowe; W R Yates; C M McChesney
Journal:  Am J Psychiatry       Date:  1987-08       Impact factor: 18.112

View more
  17 in total

1.  Correspondence (letter to the editor): One-sided publication.

Authors:  Günther Egidi
Journal:  Dtsch Arztebl Int       Date:  2013-09       Impact factor: 5.594

2.  Correspondence (letter to the editor): Regular muscle activity.

Authors:  Martin Hofmeister
Journal:  Dtsch Arztebl Int       Date:  2013-09       Impact factor: 5.594

3.  Correspondence (letter to the editor): Professional and ethical criticism.

Authors:  Wolf Müller
Journal:  Dtsch Arztebl Int       Date:  2013-09       Impact factor: 5.594

4.  Correspondence (letter to the editor): Numerous competing interests.

Authors:  Niklas Schurig
Journal:  Dtsch Arztebl Int       Date:  2013-09       Impact factor: 5.594

5.  Correspondence (reply): In reply.

Authors:  Borwin Bandelow; Reinhard J Boerner; Siegfried Kasper; Michael Linden; Hans-Ulrich Wittchen; Hans-Jürgen Möller
Journal:  Dtsch Arztebl Int       Date:  2013-09       Impact factor: 5.594

6.  Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior.

Authors:  Rolf T Hansen; Marco Conti; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

Review 7.  The diagnosis of and treatment recommendations for anxiety disorders.

Authors:  Borwin Bandelow; Thomas Lichte; Sebastian Rudolf; Jörg Wiltink; Manfred E Beutel
Journal:  Dtsch Arztebl Int       Date:  2014-07-07       Impact factor: 5.594

8.  Audio Recording for Independent Confirmation of Clinical Assessments in Generalized Anxiety Disorder.

Authors:  Steven D Targum; Christopher Murphy; Jibran Khan; Laura Zumpano; Mark Whitlock; Arthur A Simen; Brendon Binneman
Journal:  Innov Clin Neurosci       Date:  2018-04-01

9.  Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study.

Authors:  Anita R Peoples; Peter W Bushunow; Sheila N Garland; Charles E Heckler; Joseph A Roscoe; Luke L Peppone; Deborah J Dudgeon; Jeffrey J Kirshner; Tarit K Banerjee; Judith O Hopkins; Shaker R Dakhil; Marie A Flannery; Gary R Morrow
Journal:  Support Care Cancer       Date:  2015-09-02       Impact factor: 3.603

Review 10.  Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review.

Authors:  Giampaolo Perna; Alessandra Alciati; Alice Riva; Wilma Micieli; Daniela Caldirola
Journal:  Curr Psychiatry Rep       Date:  2016-03       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.